1-8 of 8
Jiangang Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal, Philip J. Ebert, Andrew J. Wagner, Jennifer Wright, Javier Martin-Broto, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2598–2608.
https://doi.org/10.1158/1078-0432.CCR-23-3936
Published: 03 June 2024
View articletitled, Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Open the PDF for Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE in another window
Includes: Supplementary data
Journal Articles

Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Alyssa C. Flint, Dana K. Mitchell, Steven P. Angus, Abbi E. Smith, Waylan Bessler, Li Jiang, Henry Mang, Xiaohong Li, Qingbo Lu, Brooke Rodriguez, George E. Sandusky, Andi R. Masters, Chi Zhang, Pengtao Dang, Jenna Koenig, Gary L. Johnson, Weihua Shen, Jiangang Liu, Amit Aggarwal, Gregory P. Donoho, Melinda D. Willard, Shripad V. Bhagwat, D. Wade Clapp, Steven D. Rhodes
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1992.
https://doi.org/10.1158/1078-0432.CCR-24-0635
Published: 01 May 2024
View articletitled, Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Open the PDF for Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma in another window
Journal Articles

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Sara M. Tolaney, Shom Goel, Jorge Nadal, Hannelore Denys, Manuel R. Borrego, Lacey M. Litchfield, Jiangang Liu, Adams K. Appiah, Yanyun Chen, Fabrice André
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 39–49.
https://doi.org/10.1158/1078-0432.CCR-23-1209
Published: 05 January 2024
View articletitled, Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Open the PDF for Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Alyssa C. Flint, Dana K. Mitchell, Steven P. Angus, Abbi E. Smith, Waylan Bessler, Li Jiang, Henry Mang, Xiaohong Li, Qingbo Lu, Brooke Rodriguez, George E. Sandusky, Andi R. Masters, Chi Zhang, Pengtao Dang, Jenna Koenig, Gary L. Johnson, Weihua Shen, Jiangang Liu, Amit Aggarwal, Gregory P. Donoho, Melinda D. Willard, Shripad V. Bhagwat, D. Wade Clapp, Steven D. Rhodes
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3438–3456.
https://doi.org/10.1158/1078-0432.CCR-22-2854
Published: 01 September 2023
View articletitled, Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Open the PDF for Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma in another window
Includes: Supplementary data
Journal Articles

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4939.
https://doi.org/10.1158/1078-0432.CCR-21-2431
Published: 01 September 2021
View articletitled, Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Journal Articles

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4870–4882.
https://doi.org/10.1158/1078-0432.CCR-19-4191
Published: 01 September 2021
View articletitled, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Sara A. Hurvitz, Miguel Martin, Michael F. Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga, Sameera Wijayawardana, Manisha Brahmachary, Philip J. Ebert, Anwar Hossain, Jiangang Liu, Adam Abel, Amit Aggarwal, Valerie M. Jansen, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 566–580.
https://doi.org/10.1158/1078-0432.CCR-19-1425
Published: 03 February 2020
View articletitled, Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Open the PDF for Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B21: Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma

Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Dan Li, Xue-Qian Gong, Sean Buchanan, James R. Henry, James J. Starling, Sheng-Bin Peng
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B21.
https://doi.org/10.1158/1078-0432.MECHRES-B21
Published: 04 March 2013
View articletitled, Abstract B21: Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma
Open the PDF for Abstract B21: Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma in another window